Tradestie Institutional Equity Comparison Engine

VRTX vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VRTX Overall Edge

VRTX Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vertex Pharmaceuticals Inc (VRTX) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, VRTX trades at 25.9x Forward P/E with 37.8% operating margin (+11.8% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, VRTX sits in CONSOLIDATION (33rd %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
VRTX 25.9x vs MRNA 23.0x Fwd P/E
Growth & Margin Winner VRTX
Op Margin 37.8% vs -80.8% ยท YoY +11.8% vs +29.2%
Momentum & Technical Winner MRNA
1Y +22.3% vs +706.5% ยท 52W Pos 66% vs 67%
Options & Structure Winner VRTX
CONSOLIDATION (33rd %ile IV) vs CONSOLIDATION (52nd %ile IV)
VRTX NASDAQ
Vertex Pharmaceuticals Inc
Pharmaceutical Preparations
$515.02
-1.08% 1D
Market Cap $132.0B
1M Return -3.77%
1Y Return +22.32%
Forward P/E 25.9x
Unified AI Score
40.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 69.0 Mom 46.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VRTX +22.32% MRNA +706.45% Spread: +684.13 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VRTX Revenue MRNA Revenue VRTX Op. Margin MRNA Op. Margin Margin Edge
FY2018 $3.05B $140M 20.8% -306.0% VRTX
FY2019 $4.16B $60M 28.8% -906.8% VRTX
FY2020 $6.21B $800M 46.0% -95.0% VRTX
FY2021 $7.57B $18.5B 36.7% 72.0% MRNA
FY2022 $8.93B $19.3B 48.2% 48.9% MRNA
FY2023 $9.87B $6.85B 38.8% -61.9% VRTX
FY2024 $11.0B $3.24B -2.1% -121.9% VRTX
FY2025 $12.0B $1.94B 34.8% -158.1% VRTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VRTX (6) vs MRNA (4)
Institutional Metric VRTX MRNA Criterion Row Winner
Market Capitalization Scale $132.0B $80.7B Larger Scale VRTX
Trailing P/E Ratio Valuation 33.5x 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation 25.9x 23.0x Lower Multiple MRNA
Revenue Growth (YoY) Growth +11.8% +29.2% Higher Growth MRNA
Operating Margin (TTM) Profitability 37.8% -80.8% Higher Margin VRTX
Net Profit Margin Profitability 30.7% -110.5% Higher Margin VRTX
Return on Equity (ROE) Capital Efficiency 20.8% -34.5% Higher ROE VRTX
52-Week Range Position Momentum 66% ($412โ€“$569) 67% ($22โ€“$281) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 0.35ฮฒ ยท 28% Vol 2.23ฮฒ ยท 78% Vol Lower Realized Risk VRTX
Unified Institutional Score Composite Signal 40.9 / 100 (SELL) 40.3 / 100 (SELL) Higher Composite VRTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VRTX vs MRNA Buy Guide
VRTX CONSOLIDATION
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 33rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live VRTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VRTX nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.